Esophageal squamous cell carcinoma
Conditions
Interventions
treatment group:Camrelizumab plus chemotherapy
control group:chemotherapy
Sponsors
Huashan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with esophageal squamous cell carcinoma diagnosed by cytology or histology; 2. Those patients who agree to collect tumor tissue and peripheral blood samples needed for research and apply them to relevant research; 3. Patients with advanced esophageal cancer who can be surgically resected without any treatment and without surgical contraindications; 4. Patients who agree to accept radical surgery; 5. Patients with at least one measurable lesion (RECIST v1.1); 6. 18 years old <= patient age <= 75 years old, male or female; 7. Patients with ECoG score 0; 8. Patients who have signed the written informed consent and can follow the visit and related procedures specified in the protocol.
Exclusion criteria
Exclusion criteria: 1. Patients who have received any anti-tumor treatment in the past, including radiotherapy, chemotherapy, immunotherapy and traditional Chinese medicine treatment (except for the treatment of malignant tumor with no recurrence and metastasis for more than 5 years); 2. Patients who had used immunosuppressive drugs within 3 weeks before the first dose of study treatment (excluding prednisone not exceeding 10 mg / day or other glucocorticoids of equivalent dose); 3. Patients with known or suspected active autoimmune diseases; 4. Patients with known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation; 5. Patients allergic to any component of monoclonal antibody; 6. Patients with other uncontrolled serious diseases; 7. Patients with other acute or chronic diseases that may interfere with the test results of the study; 8. Physical examination or clinical examination findings that researchers believe may increase the risk of adverse reactions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate(ORR);Major Pathologic Response(MPR);pathologic complete response(pCR); | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 resection rate;disease free survival(DFS);recurrence rate(RR);survival rate(SR); | — |
Countries
China
Contacts
Public ContactZhiming Chen
Huashan Hospital Affiliated to Fudan University
Outcome results
None listed